Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

172 works

Work: Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

  1. Disorders of cancer metabolism: The therapeutic potential of cannabinoids

    Dingya Sun, Xin Li, Shengdan Nie +2

    Review article20229 citations
    ABI

  2. Tumor Cell-Targeting and Tumor Microenvironment–Responsive Nanoplatforms for the Multimodal Imaging-Guided Photodynamic/Photothermal/Chemodynamic Treatment of Cervical Cancer

    Ying Wang, Yiyan Xu, Jiayu Song +8

    Article20248 citations
    ABI

  3. <scp>CHB</scp> patients with <scp>rtA181T</scp>‐mutated <scp>HBV</scp> infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes

    Qiqi Ning, Tongwang Yang, Xianghua Guo +8

    Article20238 citations
    ABI

  4. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Review article20236 citations
    ABI

  5. A <scp>TGF</scp>‐β signaling‐related <scp>lncRNA</scp> signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

    Weiwei Duan, Liting Yang, Jian Liu +13

    Article20236 citations
    ABI

  6. Exploring treatment options in cancer: tumor treatment strategies

    Beilei Liu, Hongyu Zhou, Licheng Tan +2

    Review article20245 citations
    ABI

  7. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder

    Yutao Lou, Mengting Cheng, Qin Cao +7

    Article20235 citations
    ABI

  8. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy

    Zhibin Wang, Xiu Zhang, Chao Fang +4

    Review article20244 citations
    ABI

  9. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)

    Fei Li, Jiaqi Tian, Lin Zhang +2

    Review article20244 citations
    ABI

  10. Alantolactone: structural enhancements and therapeutic insights for cancer and inflammation

    Muzaffar Kayumov, Fotima A. Sobirova, Okhunjon Khasanov +3

    Review articleSesquiterpenes and Asteraceae StudiesNatural Product Research20253 citations
    ABI

  11. Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local–national perspective

    Feng Hu, Huijie Yang, Liping Qiu +6

    Article20253 citations
    ABI

  12. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera)

    Chang Hoon Ji, Min Ju Lee, Hee Yeon Kim +5

    Other20223 citations
    ABI

  13. Co-Crystallization Approach to Enhance the Stability of Moisture-Sensitive Drugs

    Madhukiran R. Dhondale, Pradip Thakor, Amritha G. Nambiar +4

    Review article20232 citations
    ABI

  14. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

    Jill Hallin, Lars D. Engstrom, Lauren Hargis +31

    Article20192 citations
    ABI

  15. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

    Longchuan Bai, Haibin Zhou, Renqi Xu +15

    Article20192 citations
    ABI

  16. Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

    Ian Churcher

    Review article20172 citations
    ABI

  17. AUTACs: Cargo-Specific Degraders Using Selective Autophagy

    Daiki Takahashi, Jun Moriyama, Tomoe Y. Nakamura +6

    Article20192 citations
    ABI

  18. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance

    Xin Lin, Hua Xiang, Guoshun Luo

    Review article20202 citations
    ABI

  19. Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

    Adam D. Cotton, Duy Nguyen, Josef A. Gramespacher +2

    Article20212 citations
    ABI

  20. Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

    Heng Zhang, Yu Han, Yuanfan Yang +7

    Article20212 citations
    ABI

  21. PROTAC targeted protein degraders: the past is prologue

    Miklós Békés, David R. Langley, Craig M. Crews

    Review article20222 citations
    ABI

  22. Proteolysis-targeting chimeras (PROTACs) in cancer therapy

    Xinyi Li, Wenchen Pu, Qingquan Zheng +3

    Article20222 citations
    ABI

  23. Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein–Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases

    Fengzhi Li, Ieman Aljahdali, Xiang Ling

    Review article20222 citations
    ABI

  24. Targeted Protein Degradation via Lysosomes

    Rishi R. Paudel, Dong Lu, Sandipan Chowdhury +2

    Review article20222 citations
    ABI

  25. Targeted Protein Degradation: Clinical Advances in the Field of Oncology

    Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova +1

    Review article20222 citations
    ABI